Liao Bin-Chi, Lin Chia-Chi, Yang James Chih-Hsin
Department of Oncology, National Taiwan University Hospital, 7, Chung-Shan South Road, Taipei, Taiwan.
National Taiwan University Cancer Center, College of Medicine, National Taiwan University, Taipei, Taiwan.
Curr Oncol Rep. 2017 Jan;19(1):4. doi: 10.1007/s11912-017-0560-2.
Afatinib, a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been approved worldwide as a first-line treatment for advanced non-small cell lung cancer (NSCLC) that harbors activating EGFR mutations. Here, we have reviewed the recent clinical developments in the treatment of lung cancer using afatinib. Emerging data have revealed the overall survival benefit of first-line afatinib therapy in patients with advanced EGFR -positive NSCLC. Phase III studies of afatinib have shown the effectiveness of afatinib as a second-line treatment for advanced lung squamous cell carcinoma, as well as the benefit of continuing afatinib therapy in combination with cytotoxic chemotherapy for advanced NSCLC after the occurrence of disease progression in patients who are receiving afatinib monotherapy. Therapeutic benefits of afatinib have also been reported in studies of patients with central nervous system metastasis and patients with HER2 mutation. The utility of afatinib-based combination therapies is being investigated in ongoing research.
阿法替尼是一种第二代表皮生长因子受体（EGFR）酪氨酸激酶抑制剂，已在全球范围内被批准作为一线治疗药物，用于治疗携带激活型EGFR突变的晚期非小细胞肺癌（NSCLC）。在此，我们回顾了使用阿法替尼治疗肺癌的近期临床进展。新出现的数据显示，一线使用阿法替尼治疗对晚期EGFR阳性NSCLC患者具有总生存获益。阿法替尼的III期研究表明，阿法替尼作为晚期肺鳞状细胞癌的二线治疗药物是有效的，并且对于接受阿法替尼单药治疗后疾病进展的晚期NSCLC患者，继续将阿法替尼与细胞毒性化疗联合使用也有益处。在中枢神经系统转移患者和HER2突变患者的研究中也报道了阿法替尼的治疗益处。目前正在进行的研究中，正在探究以阿法替尼为基础的联合疗法的效用。
